{"id":605668,"date":"2026-09-07T10:46:52","date_gmt":"2026-09-07T13:46:52","guid":{"rendered":"https:\/\/portatilandaimes.com.br\/?p=605668"},"modified":"2026-09-07T10:46:52","modified_gmt":"2026-09-07T13:46:52","slug":"temozolomid-a-jeho-davkovanie-peptidov","status":"publish","type":"post","link":"https:\/\/portatilandaimes.com.br\/?p=605668","title":{"rendered":"Temozolomid a jeho d\u00e1vkovanie peptidov"},"content":{"rendered":"

Temozolomid je chemoterapeutick\u00fd liek, ktor\u00fd sa \u010dasto pou\u017e\u00edva v lie\u010dbe ur\u010dit\u00fdch typov rakoviny, najm\u00e4 glioblast\u00f3mu. Jeho \u00fa\u010dinnos\u0165 z\u00e1vis\u00ed od mnoh\u00fdch faktorov, vr\u00e1tane spr\u00e1vneho d\u00e1vkovania a kombin\u00e1cie s r\u00f4znymi lie\u010divami, ako s\u00fa peptidy, ktor\u00e9 m\u00f4\u017eu zlep\u0161i\u0165 jeho terapeutick\u00e9 \u00fa\u010dinky.<\/p>\n

Temozolomid a jeho d\u00e1vkovanie peptidov<\/a> sa st\u00e1va \u010doraz popul\u00e1rnej\u0161ou t\u00e9mou v oblasti onkol\u00f3gie, preto\u017ee s\u00fa\u010dasn\u00e9 v\u00fdskumy nazna\u010duj\u00fa, \u017ee synergick\u00e9 p\u00f4sobenie peptidov m\u00f4\u017ee vies\u0165 k zlep\u0161eniu \u00fa\u010dinnosti a zn\u00ed\u017eeniu ved\u013eaj\u0161\u00edch \u00fa\u010dinkov lie\u010dby.<\/p>\n

1. V\u00fdznam peptidov v onkol\u00f3gii<\/h2>\n

Peptidy, kr\u00e1tke re\u0165azce aminokysel\u00edn, hraj\u00fa v\u00fdznamn\u00fa \u00falohu v biologick\u00fdch procesoch a m\u00f4\u017eu c\u00edti\u0165 vo\u013en\u00e9 radik\u00e1ly, stimulova\u0165 imunitn\u00fd syst\u00e9m alebo priamo zasahova\u0165 do bunkov\u00e9ho cyklu rakovinov\u00fdch buniek. V posledn\u00fdch rokoch sa uk\u00e1zalo, \u017ee kombin\u00e1cia temozolomidu s ur\u010dit\u00fdmi peptidmi m\u00f4\u017ee pozit\u00edvne ovplyvni\u0165 v\u00fdsledok lie\u010dby.<\/p>\n

2. D\u00e1vkovanie temozolomidu<\/h2>\n

Stanovenie spr\u00e1vneho d\u00e1vkovania je k\u013e\u00fa\u010dov\u00e9 pre \u00faspe\u0161n\u00fa lie\u010dbu. \u0160tandardne sa temozolomid pod\u00e1va v nasleduj\u00facich re\u017eimoch:<\/p>\n

    \n
  1. D\u00e1vka 75 mg\/m\u00b2 denne po\u010das 42 dn\u00ed s n\u00e1slednou 28-d\u0148ovou prest\u00e1vkou.<\/li>\n
  2. Alternat\u00edvne d\u00e1vkovanie 150-200 mg\/m\u00b2 po\u010das 5 dn\u00ed po dobu 28-d\u0148ov\u00e9ho cyklu.<\/li>\n<\/ol>\n

    D\u00e1vkovanie m\u00f4\u017ee by\u0165 prisp\u00f4soben\u00e9 na z\u00e1klade tolerancie pacienta a odpovede na lie\u010dbu.<\/p>\n

    3. Kombin\u00e1cia s peptidmi<\/h2>\n

    V s\u00fa\u010dasnosti prebiehaj\u00fa r\u00f4zne klinick\u00e9 \u0161t\u00fadie, ktor\u00e9 sk\u00famaj\u00fa vyu\u017eitie peptidov v kombin\u00e1cii s temozolomidom. Tieto \u0161t\u00fadie sa zameriavaj\u00fa na nasleduj\u00face aspekty:<\/p>\n

      \n
    1. Zlep\u0161enie prieniku lie\u010diva do n\u00e1dorov.<\/li>\n
    2. Zn\u00ed\u017eenie rezistencie rakovinov\u00fdch buniek na lie\u010dbu.<\/li>\n
    3. Minimaliz\u00e1cia ved\u013eaj\u0161\u00edch \u00fa\u010dinkov spojen\u00fdch s chemoterapiou.<\/li>\n<\/ol>\n

      4. Z\u00e1ver<\/h2>\n

      Kombin\u00e1cia temozolomidu s peptidmi predstavuje s\u013eubn\u00fa oblas\u0165 v\u00fdskumu, ktor\u00e1 by mohla zlep\u0161i\u0165 v\u00fdsledky lie\u010dby rakoviny. D\u00e1vkovanie by malo by\u0165 v\u017edy prisp\u00f4soben\u00e9 individu\u00e1lnym potreb\u00e1m pacienta a pod doh\u013eadom odborn\u00edkov. Monitorovanie \u00fa\u010dinnosti a ved\u013eaj\u0161\u00edch \u00fa\u010dinkov je k\u013e\u00fa\u010dov\u00e9 pre optimaliz\u00e1ciu lie\u010debn\u00e9ho procesu.<\/p>\n","protected":false},"excerpt":{"rendered":"

      Temozolomid je chemoterapeutick\u00fd liek, ktor\u00fd sa \u010dasto pou\u017e\u00edva v lie\u010dbe ur\u010dit\u00fdch typov rakoviny, najm\u00e4 glioblast\u00f3mu. Jeho \u00fa\u010dinnos\u0165 z\u00e1vis\u00ed od mnoh\u00fdch faktorov, vr\u00e1tane spr\u00e1vneho d\u00e1vkovania a kombin\u00e1cie [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"audio","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-605668","post","type-post","status-publish","format-audio","hentry","category-sem-categoria","post_format-post-format-audio"],"_links":{"self":[{"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=\/wp\/v2\/posts\/605668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=605668"}],"version-history":[{"count":1,"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=\/wp\/v2\/posts\/605668\/revisions"}],"predecessor-version":[{"id":605669,"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=\/wp\/v2\/posts\/605668\/revisions\/605669"}],"wp:attachment":[{"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=605668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=605668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/portatilandaimes.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=605668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}